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Effects of diabetes and insulin on expression of kallikrein and renin
genes in the kidney. We previously showed that renal prokallikrein
synthesis is reduced in streptozotocin (STZ)-diabetic rats. Plasma renin
activity is also reduced in diabetic rats. To investigate the molecular
mechanisms underlying these changes, we examined the effects of
diabetes and insulin treatment on renal kallikrein and renal renin mRNA
levels and the activities of these enzymes. Rats made diabetic by STZ
were either treated with 1.5 to 1.75 U PZI insulin daily to maintain
moderate hyperglycemia (plasma glucose 200 to 300 mg/dl, D + I) or left
untreated to produce severe hyperglycemia (plasma glucose > 400
mg/dl, D). Control (C) rats were also studied. After three weeks, renal
kallikrein mRNA was reduced 50% in D rats. A proportional reduction
in immunoreactive kallikrein was also observed (37.8 2.5 vs. 55.8
6.8 ng/mg protein, D vs. C, P < 0.001). Kallikrein mRNA and
irnmunoreactive kallikrein levels in D + I rats were not different from C
rats. Renin mRNA level was also markedly reduced in D rats, com-
pared to C rats. This was associated with reduced plasma renin
concentration (4.5 0.2 vs. 10.5 1.6 ng Ang I/ml/hr, D vs. C, P <
0.01). However, renal renin concentration was unchanged (0.84 0.17
vs. 0.84 1.3 sg Ang I/mg protein/hr, D vs. C). In D + I rats, renin
mRNA level and plasma renin concentration were not different from C
levels. However, renal renin concentration was increased (1.49 0.27
jg Ang I/mg protein/br) compared to C rats (P < 0.05). /3-actin mRNA
levels were unchanged in either diabetic rat group. These data show
that the diabetic state suppresses kallikrein and renin mRNA levels.
Insulin treatment reverses the reductions in message levels and results
in normal or increased tissue enzyme activities.
Glomerular hyperfiltration has been consistently observed in
patients with insulin-dependent diabetes, as well as in early
stages of experimental diabetes [1—6]. Micropuncture studies in
diabetic rats have shown that hyperfiltration occurs as a result
of reduced glomerular arteriolar resistances, resulting in in-
creases in glomerular plasma flow and mean capillary hydraulic
pressure [3, 4]. These early hemodynamic disturbances have
been suggested to contribute to the initiation and progression of
diabetic glomerulopathy [7]. Amelioration of glomerular capil-
lary hypertension by treatment with angiotensin-converting
enzyme inhibitors prevents the development of nephropathy in
streptozotocin-diabetic rats [8]. Although the factor(s) which
mediate altered glomerular hemodynamics in diabetes have not
been clearly defined, recent findings support a role for the renal
kallikrein-kinin system (KKS) and renin-angiotensin system
(RAS).
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We have shown that severely hyperglycemic diabetic rats not
treated with insulin have reduced renal prokallikrein synthesis
and activation [9, 10]. Impaired synthesis and activation results
in reduced tissue and urinary active kallikrein. These changes
are associated with increased renal vascular resistance and
reduced renal plasma flow (RPF). In contrast, diabetic rats
given insulin to maintain moderate hyperglycemia show in-
creased renal and urinary active kallikrein in association with
reduced renal vascular resistance, and increased RPF and GFR
[lii. Treatment of these rats with aprotinin, a kallikrein inhib-
itor, or a kinin receptor antagonist reduces GFR and RPF to
levels not different from normal rats [11]. We also find increased
renal excretion of active kallikrein in hyperfiltering type I
diabetic patients [121.
The activity of the RAS in diabetes has been reported to be
increased, decreased, or unchanged. Diabetic rats with severe
hyperglycemia show reduced plasma renin activity (PRA) while
moderately hyperglycemic diabetic rats show an increase or no
change in plasma renin activity [13—17]. In clinical studies,
reduced plasma renin activity has been observed in diabetic
patients with nephropathy and other complications [18]. On the
other hand, some studies have found that diabetic patients with
hyperfiltration have increased plasma renin activity [19, 20].
Most of the information regarding renin changes in diabetes has
been derived from measurements of its plasma activity. Al-
though informative, they may not reflect the intrarenal activity
of the system.
In the present study we measured both kallikrein and renin
activity in kidneys of streptozotocin-diabetic rats, together with
the levels of mRNA's that encode these enzymes. In addition,
we examined the effects of insulin treatment on expression of
these genes.
Methods
Treatment protocols
Male Sprague-Dawley rats (Charles River Breeding Labora-
tories, Inc., Wilmington, Massachusetts, USA) weighing 200 to
220 g were used in these studies. Rats were housed three to four
per cage and had free access to water and regular chow.
Diabetes was induced by a single tail vein injection of strepto-
zotocin (STZ), 65 mg/kg body weight. STZ was a gift from the
Upjohn Co. (Kalamazoo, Michigan, USA). After 24 hours,
diabetes was confirmed in STZ-treated rats by tail vein plasma
glucose levels, Rats were excluded if their plasma glucose
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levels were <250 mg/dl. Glucose levels and body weights were
subsequently measured at intervals to characterize the diabetic
state. Age-matched control (C) rats were also studied.
The diabetic rats were divided into two groups. The first
group (D) received no insulin treatment and displayed severe
hyperglycemia. Plasma glucose levels were >400 mg/dl
throughout three weeks of study. The second group of diabetic
rats (D + I) was treated daily with 1.5 to 1.75 U protamine zinc
insulin (PZI, Lilly, Indianapolis, Indiana, USA). Insulin was
begun 24 hours after STZ injection, and plasma glucose levels
were maintained in the range of 200 to 300 mg/dl over the three
week study period. Because of limitations on the number of
RNA samples that could be processed at one time, two to three
rats from each group were studied together on three separate
occasions to provide a total of seven rats in each diabetic group
and eight control rats.
At three weeks, control and both diabetic groups of rats were
killed by decapitation. Blood was collected in iced EDTA-
coated tubes for measurement of plasma renin concentration.
One kidney from each rat was bisected longitudinally through
the renal pelvis and stored at —20°C. One half was subsequently
used for measurement of immunoreactive kallikrein level and
the other half for renin concentration. Total protein concentra-
tion was measured in each half. The other kidney was proc-
essed immediately to measure kallikrein, renin and f3-actin
messenger RNA levels by Northern and dot blot analyses,
utilizing kallikrein, renin and p-actin cDNA probes.
RNA extraction
Kidney tissue was minced and homogenized with a polytron
(1 mm) in GIT buffer (4 M Guanidine thiocyanate, 3 M sodium
acetate, 0.1 M 2-mercaptoethanol). The homogenate was ultra-
centrifuged (174,000 g at 20°C for 21 hrs) over a cesium chloride
gradient (5.7 M CsCl, 3 M sodium acetate). The resulting RNA
pellet was dissolved in diethyl pyrocarbonate treated water and
the RNA concentration was determined in a spectrophotometer
by absorbance at 260 nm. Total RNA extracted by this proce-
dure had a A260/A280 ratio of 1.98 0.01.
cDNA probe preparations
Double-stranded tissue kallikrein cDNA insert, about 500 bp
in length [21], was prepared from Ml3 mpr 8 DNA by restric-
tion digestion (Eco RI/Bam HI), followed by agarose gel
eleetrophoresis and electroelution. The renin cDNA (pRen 44.
ceb) was isolated from rat kidney gt-l0 cDNA library and
subcloned in the plasmid pGEM4 [22]. The insert is about 1,425
bp and was a gift of Dr. K.R. Lynch (University of Virginia,
Charlottesville, Virginia, USA). f3-actin eDNA insert is about
540 bp and was a gift of Dr. J. Norris (Medical University of
South Carolina, Charleston, South Carolina, USA). All three
eDNA probes were labelled with 32P (New England Nuclear
Research Products, Boston, Massachusetts, USA), using a
Nick-translation kit (Bethesda Research Laboratories, Be-
thesda, Maryland, USA) according to the procedures recom-
mended by the supplier, Unincorporated label was removed by
spin-column (G-50), and the specific activity of each probe was
around I to 2 x 108 cpm/tg DNA.
Northern blot hybridization
RNA hybridization analysis was performed essentially as
described by Thomas [231. Total RNA (30 pg), obtained as
described above, was mixed with 10 jxl 100% formamide, 4 1.d
37% formaldehyde and 2 d 10 x MOPS buffer (40 m sodium
acetate, 5 m EDTA, pH 7.0), denatured at 65°C for 15
minutes, and run on a 1.5% agarose gel containing 2.2 M
formaldehyde in I x MOPS buffer. The gel was stained with
ethidium bromide to determine the position in each lane of the
28S and l8S ribosomal RNA and to demonstrate that similar
amounts of intact RNA were used for each sample. Total RNA
was transferred from the gel to Immobilon-N membrane filters
by capillary elution of 20 x SSC solution (3 M NaCl2, 0.3 M Na3
citrate, pH 7.0) for at least 15 hours. The Immobilon-N mem-
branes were baked for at least two hours at 80°C in a vacuum
oven and prehybridized at 60°C for three hours in a solution
containing 6 x SSC, 5 )< Denhardt's solution (1% Ficol, 1%
polyvinyl pyrolidone and 1% bovine serum albumin), 1% SDS
and 100 xg!ml denatured salmon sperm DNA. The membranes
were then hybridized for 16 to 18 hours at 60°C with nick-
translated cDNA probes, prepared as described above. The
hybridized membranes were washed three times for 15 minutes
each time at room temperature in 3 X SSC, 0.1% SDS, and two
times, 15 minutes each, at 60°C in 3 x SSC, 0.1% SDS.
Autoradiographs (Kodak XAR-5 film, Eastman Kodak, Roch-
ester, New York, USA) of the membranes were obtained and
quantitated by a Joyce Loebl microdensitometer 3GS.
Since two to three rats from each group were studied together
in three separate experiments, the quantitative densitometric
measurements on the Northern blots were normalized as a
percentage of the average density of the controls performed in
that particular experiment.
Dot blot hybridization
Aliquots of total RNA were serially diluted with water (10 to
0.62 xg), mixed with formamide, formaldehyde and 20 x SSC,
and incubated at 68°C for 15 minutes, The denatured RNA
solution was applied to the slots of a manifold (Schleicher and
Schull) and slowly filtered onto nitrocellulose membranes. The
wells of the manifold were rinsed with I ml of 10 x SSC, and the
nitrocellulose filters were then removed and baked for two
hours at 80°C in a vacuum oven. Prehybridization and hybrid-
ization of the membrane filters were carried out as described
above for Northern blot. Autoradiographs (Kodak XAR-5 film)
were obtained and quantitated by densitometry.
Kallikrein assay
Kidney tissue was prepared for kallikrein assay as previously
described [9]. Briefly, kidneys were minced and homogenized
with a teflon glass homogenizer in 1.5 ml of phosphate buffered
saline, pH 7.4. Sodium deoxycholate (0.5% final concentration)
was added to the homogenate, and after incubation for one hour
at 4°C, the homogenate was centrifuged at 27,000 g for 30
minutes at 4°C. The resulting supernatant was used for mea-
surement of immunoreactive kallikrein and total protein con-
centration.
Active and prokallikrein levels were measured by a radioim-
munoassay that incorporates a monoclonal antibody specific for
active kallikrein. As described previously [24], active kallikrein
Jaffa et a!: Kallikrein and ream gene expression in diabetes 791
was measured directly, and total kallikrein was measured in a
second sample aliquot in which prokallikrein was converted to
active kallikrein by prior trypsin treatment. Prokallikrein con-
centration was derived by subtracting active from total kal-
likrein.
Renin assays
Plasma renin concentration (PRC) and renal renin concentra-
tion were determined from the amount of generated angiotensin
I (Ang I), using a kit (Biotecx Lab, Inc., Friendswood, Texas,
USA). Kidney renin was extracted according to the method of
Naftilan and Oparil [25]. Kidneys stored at —20°C were thawed
at room temperature and refrozen. This procedure was repeated
three times over three successive days. The thawed tissue was
then homogenized in 0.9% sodium chloride, containing EDTA
(1% wt/vol), pH 4.9. The homogenate was centrifuged at 35,000
g for 90 minutes, and the supernatant was retained. The pellet
was resuspended in the saline solution and centrifuged for 30
minutes at 35,000 g. The supernatant fractions were combined
and renin activity was measured. Incubation of the extract with
graded concentrations of trypsin produced no increase in renin
activity (1.33 0.24 vs. 1.36 0,27 g Ang I/mg prot/hr). Thus,
all of the prorenin was activated during tissue processing.
Generation of Ang I was carried out by adding 0.1 ml of renin
substrate (plasma from rats nephrectomized for 48 hr) to 0.5 ml
of plasma or 20 d of kidney extract, the latter diluted 1:200 with
saline-EDTA solution, pH 4.9. These samples were incubated
at 37°C for 15 to 30 minutes [13]. Angiotensin I generation
during the incubation period was linear, and nephrectomized rat
plasma did not generate Ang I. Activity was corrected for
dilution of the sample with substrate plasma, and renin concen-
tration was expressed as ng Ang I/mI plasma/hr incubation or
tg Ang I/mg renal protein/hr.
Other assays
Plasma glucose levels were measured with a Glucose Ana-
lyzer 2 (Beckman, Fullerton, California, USA). Protein concen-
tration was measured by the method of Lowry Ct a! [26], using
bovine serum albumin as standard.
Statistical analysis
Data are expressed as mean SEM. Differences were as-
sessed by analysis of variance. Intergroup differences were then
analyzed by Student's f-test for unpaired data. Densitometric
data that were normalized were analyzed by the Wilcoxon rank
sum test. Differences were considered significant at a level of P
<0.05.
Results
Characteristics of diabetic rats
After three weeks, untreated diabetic (D) rats showed signif-
icantly lower body weight compared to either control (C) or
insulin-treated diabetic (D + I) rats (Table 1). The average
weight gain in D rats was 2.46 0.76 glday compared to 7.92
0.25 g in C or 7.22 0.39 g/day in D + I rats. In contrast, left
kidney weight in D rats was significantly greater than that in C
or D + I rats (Table 1). Plasma glucose levels were significantly
elevated in both diabetic groups. However, at the end of three
weeks, the D rats had higher (P < 0.001) plasma glucose levels
Table 1. Body weight, plasma glucose level and left kidney weight in
control (C), diabetic (D) and insulin-treated diabetic (D + I) rats
Left kidney
Body weight Plasma glucose weight
g meld! g
C (N = 8) 392 6 143 8 1.37 0.06
D(N = 7) 283 14 525 21 1.79 o.09
D+I(N=7) 352±8 248±33" 1.45±0.11
a P < 0.05 or less vs. C and D + Ib P < 0.01 vs. C
0
Total Active Prokallikrein
Fig. 1. Renal tissue kallikrein levels in control (solid bar), diabetic
(stippled bar) and insulin-treated diabetic (open bar) rats. Tissue levels
were measured three weeks after induction of diabetes. Diabetic (D)
rats had reduced renal active kallikrein and these changes were pre-
vented by insulin treatment (D + I). Prokallikrein levels were un-
changed. * < 0.001 vs. C.
(525 21 mg/dl) than C (143 8 mg/dl) or D + 1(248 33
mg/dl).
Renal kallikrein and kallikrein mRNA levels
Renal tissue levels of total, active and prokallikrein in C, D
and D + I rats are shown in Figure 1. A reduction in total
kallikrein in D rats is principally accounted for by reduced
active kallikrein (active: 23.4 1.5 vs. 36.3 3.9 ng/mg
protein, D vs. C, respectively, P < 0.001). Renal prokallikrein
levels were not significantly reduced by the diabetic state (14.4
1.4 vs. 19.4 3.4 ng/mg protein, D vs. C, respectively).
Active and prokallikrein levels in D + I rats were similar to
levels in C rats (active: 38.2 4.6 ng/mg protein; prokallikrein:
21.6 4.8 ng/mg protein).
Northern blots showed a single band for renal kallikrein
mRNA of approximately 800 to 900 base pairs. Figures 2 and 3
are representative autoradiographs of Northern and dot blots of
RNA extracted from kidneys of C, D and D + I rats. Quanti-
tative densitometry of the Northern blots from all of the rats in
each group showed that the kallikrein mRNA in D rats was
reduced to 47% of the level in C rats (P < 0.001). Kallikrein
mRNA levels in the D + I rats were 74% of control levels,
higher than in D rats (P < 0.01) but not significantly different
from control levels.
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Discussion
Fig. 2. Autoradiograph of Northern blot of total kidney RNA (30 jig)
extracted from control (C), diabetic (D) and insulin-treated diabetic (D
+ 1) rats. A 92P-labelled nick-translated kallikrein cDNA probe was
used for hybridization. The autoradiograph was exposed for 24 hours.
The diabetic rat shows a marked reduction in kallikrein rnRNA that is
reversed with insulin treatment.
Renin concentration and mRNA levels
Plasma and renal renin concentrations in C, D and D + I rats
are shown in Table 2. PRC in D rats was significantly lower than
inC rats (4.53 0.19 vs. 10.50 1.61 ng Ang I/ml/hr, D vs. C,
respectively, P < 0.02). However, intrarenal renin concentra-
tion was nearly identical in D and C rats (0.84 0.17 vs. 0.84
0.13 sg Ang I/mg protein/hr, D vs. C, respectively). In contrast,
intrarenal renin concentration was significantly increased in D
+ I rats (1.49 0.27 rg Ang I/mg protein/hr, P < 0.05 vs. C).
This increase in intrarenal renin was not associated with in-
creased PRC in D + I rats (8.78 1.8 ng Ang I/ml/hr).
Analysis of the Northern blots confirmed a single band for
renal renin mRNA of approximately 1,400 base pairs. As shown
in representative Northern and dot blots (Figs. 4 and 5), there
was a marked reduction in renal renin mRNA levels in the
kidneys of D rats, compared to kidneys of C or D + I rats.
Quantitative densitometry of the Northern blots from all of the
rats indicated that the renin mRNA level in D rats averaged 45%
of the level in C rats (P < 0.001). In D + I rats, the level
increased to 86% of control, a level not different from control.
/3-actin mRNA level
In the same rats in which kallikrein and renin message were
measured, /3-actin mRNA levels were quantitated. Neither
diabetic group showed a change in renal /3-actin mRNA com-
pared to control rats.
These data clearly show that the diabetic state reduces both
kallikrein and renin mRNA levels in the kidney and that insulin
treatment reverses these abnormalities. This is the first report
of reduced kallikrein gene expression in a disease state, We
previously reported that prokallikrein synthesis is impaired in
kidney and colon of STZ-diabetic rats, and the present findings
indicate that in the kidney this impairment is likely to be due to
reduced mRNA, possibly the result of reduced transcription of
the kallikrein gene. Although it cannot be concluded from these
data that insulin directly regulates kallikrein message levels,
some of our earlier observations suggest that this might be the
case. We previously found that insulin administration acutely
increased kallikrein synthesis rate in the colon of diabetic rats,
and chronic experimental hyperinsulinemia resulted in raised
renal kallikrein synthesis in normal rats [9, 27].
Several previous studies have indicated that the diabetic state
is associated with reduced renin activity. Reduced plasma renin
activity has been reported in STZ-diabetic rats and humans with
diabetic nephropathy [13—15, 181. Impaired prorenin activation
is implicated as a cause for this reduction in humans [28]. Our
data suggest that reduced renin mRNA might also reduce renin
production in the kidney. In addition to our data, there are two
reported preliminary studies of renin message in the STZ-
diabetic rat. One found reduced renal renin mRNA and PRA
after three weeks of diabetes [29]. However, another described
no change in mRNA levels after 12 days [301. Given that we too
studied rats after three weeks of diabetes, the different results in
the latter study may be related to the length of diabetes.
Interestingly, we observed low PRC associated with reduced
renal renin mRNA, but renal tissue renin concentration was not
reduced. Others have also found reduced PRA but normal renal
renin content in STZ-diabetic rats [14]. If renin synthesis is
reduced in kidneys because of reduced mRNA available for
translation, the normal tissue renin concentration together with
reduced PRC suggests that renin secretion into plasma may be
impaired. Indeed, there is evidence that diabetes impairs renal
renin release [14]. Since the methods we and others have used
to extract renin from the kidney result in all of the renin being
in active form, we cannot speculate as to whether impaired
prorenin activation in the kidney might also contribute to the
reduction in PRC. In any case, collective evidence now exists
that the diabetic state alters the mRNA level, the zymogen
processing and the secretion of renin. Similarly, our collective
studies indicate that several steps in kallikrein regulation are
impaired by diabetes, that is, reductions in kallikrein mRNA
level, prokallikrein synthesis, prokallikrein activation and renal
excretion of active kallikrein 19—121. It must be noted that
although reduced transcription of their genes is most likely
responsible for the reductions in kallikrein and renin mRNA
levels, reduced stability of the messages could also cause these
changes.
Although we did not measure food intake in this study, it is
likely that the untreated diabetic rats consumed more food than
the other groups, yet their rate of growth was reduced. It is
reasonable to consider whether such an increase in food intake
could have produced the changes in renin and kallikrein we
observed. Although decreased intake of sodium increases renin
mRNA over weeks, the effect of raising intake above normal is
+
o a a
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Table 2. Plasma and renal renin concentrations in control (C),
diabetic (D) and insulin-treated diabetic (D + I) rats
Renin concentration
Plasma Kidney
ngAng I/mi/hr p.g Ang I/mg prof/hr
C (N 8) 10.50 1.61 0.84 0.13
D (N = 7) 4.53 0.19b 0.84 0.17
D + 1 (N = 7) 8.78 1.18 1.49 0.27a
a P < 0.05 vs. C and D
b P < 0.02 vs. C and D + I
Fig. 3. Dot blot technique showing decreased
renal kallikrein mRNA level in diabetic (D) rat
compared to either control (C) or insulin-
treated diabetic (D + 1) rats. Total RNA (10
g) was placed in the first well, followed by
serial twofold dilutions in subsequent wells.
Autoradiograph exposure was 48 hours.
unknown [31]. Sodium restriction raises renal kallikrein synthe-
sis, but effects on message level have not been examined, and
the effects of high sodium intake have not been examined [321.
An increase in protein intake raises rather than lowers renal
kallikrein synthesis, and our recent preliminary observations
show that renal kallikrein message increases in rats fed a high
protein diet [331. An increase, not a decrease, in renin mRNA
has also been observed in rats fed high protein [34]. Therefore,
changes in protein intake are unlikely to explain our data.
Given reduced growth rate in diabetic rats, the reduced levels
of mRNA we observed might simply reflect an overall reduced
rate of protein synthesis in sick animals. Despite reduced
growth in these animals, renal growth was actually accentuated
and kidney weight was greater at the end of the study in
untreated diabetic rats (Table 1). Moreover, p-actin mRNA
levels were unchanged in the diabetic rats we studied, and there
are reports that mRNA levels for some proteins are increased in
the diabetic kidney [35, 36]. Thus, overall malnutrition is
unlikely to explain reduced kallikrein and renin mRNA levels.
Our finding of increased renal renin concentration in insulin-
treated diabetic rats is of interest. Anderson et al [371 have
reported preliminary observations that renal renin content is
increased in this model, which also displays glomerular hyper-
Fig. 4. Autoradiograph of Northern blot of total kidney RNA extracted
(30 p.g)from control (C), diabetic (D) and insulin-treated diabetic (D +
I) rats. A 32P-labelled nick-translated renin cDNA probe (pRen 44.ceb)
was used for hybridization. The autoradiograph was exposed for 23
hours. The diabetic rat shows a marked reduction in renin mRNA level
that is reversed with insulin treatment.
filtration and increased glomerular capillary hydraulic pressure
[3, 41. Treatment with converting enzyme inhibitors lowers
glomertilar pressure, suggesting that raised intrarenal renin
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the renal vasculature as well as the inherent sensitivity of
diabetic vessels to these factors needs to be understood to fully
explain the hemodynamic changes.
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Fig. 5. Dot blot analysis showing decreased renal renin mRNA level in
diabetic (D) compared to either control (C) or insulin-treated diabetic
(D + 1) rats. Total RNA (10 jig) was placed in the first well, followed by
serial twofold dilutions in subsequent wells. The exposure time of the
autoradiograph was 50 hours.
activity may contribute to glomerular hypertension in these rats
[8]. Although not observed in the present study, we reported in
two previous studies that insulin-treated, moderately hypergly-
cemic diabetic rats also show increased renal levels of active
kallikrein [11]. It is not clear why we did not find increased
kallikrein in D + I rats in the present study. In our earlier
studies, insulin-treated rats gained weight normally, whereas in
the present study body weight tended to be lower in D + I than
control rats. Given that the kallikrein message level in D + I
was returned to 74% of control, it is possible that a longer
period of insulin treatment or higher doses may be required to
completely normalize mRNA level and raise tissue kallikrein
level above normal.
The changes in renin (vasoconstrictor) and kallikrein (vaso-
dilator) activities together may contribute to the contrasting
renal hemodynamic abnormalities in severe and moderate
states of hyperglycemia [3, 11]. If renal kallikrein activity
increases in moderate hyperglycemia, increased vasodilatory
action of generated kinins could reduce glomerular arteriolar
resistances. The associated increase in intrarenal renin may
modulate kinin's action on the efferent arteriole, the site of
greater angiotensin II sensitivity [38, 39]. It is principally such
an imbalance in pre- and post-glomerular resistances that ele-
vates glomerular flow, filtration and intraglomerular pressure in
this model [3, 8]. Functional studies with receptor antagonists
of either angiotensin II [37] or kinins (unpublished observa-
tions) support the role of both peptides. In contrast, severe
hyperglycemia reduces renal kallikrein activity in concert with
normal renal renin activity. In this state the vasoregulatory
balance may be weighted towards constriction, with increased
glomerular arteriolar resistance reducing perfusion and filtra-
tion. Clearly, the entire milieu of vasoactive factors influencing
Reprint requests to Dr. Ayad A. Jaffa, Department of Medicine,
Medical University of South Carolina, 171 Ashley Avenue, Charleston,
South Carolina 29425, USA.
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